Faricimab as Treatment for Sarcoid Uveitis With Refractory Cystoid Macular Edema

<b>Purpose:</b> To describe the first use of the bispecific monoclonal antibody faricimab for sarcoid uveitis with refractory cystoid macular edema (CME). <b>Methods:</b> A single case was evaluated. <b>Results:</b> An 82-year-old woman presented with blurred vision and signs of sarcoid uveitis bilaterally, including swollen optic discs with disc nodules, CME with chorioretinal peripheral lesions in the right eye and segmental periphlebitis in the left eye. Treatment with intravitreal faricimab was initiated after systemic and topical prednisolone and oral ibuprofen failed. Significant improvement in the patient's best-corrected visual acuity and central subfield thickness was seen after 2 faricimab injections. Optical coherence tomography showed resolution of the intraretinal cyst and CME. Color fundus photography also showed improvement in the optic disc swelling and resolution of the retinal macroaneurysm. <b>Conclusions:</b> Faricimab can be a promising treatment for refractory CME in patients with sarcoid uveitis.